MPN Updates from ASCO 2019
Today the American Society of Clinical Oncology is wrapping up their 2019 ASCO meeting held annually in Chicago, IL. Although ASCO does not focus solely on blood cancers, the MPN Research Foundation looks forward to attending each year to discuss the status of MPN research and treatments with oncology professionals, drug companies, and fellow advocacy groups.
Click the links below to read the abstracts and updates pertaining to MPN related science that was presented at ASCO 2019.
- Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients
- Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.
- Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.
Stay tuned. The next conference with MPN news and updates will be at the annual American Society of Hematology conference in December 2019.